Navigation Links
PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals
Date:11/23/2011

>:  Mr. Mantick has over 25 years of experience in the pharmaceutical and biotech industries.  Prior to joining PAREXEL, he served as an Executive Director at Abt Bio-Pharma Solutions, Inc.where he led the Observational Studies/Registries Business Unit. Previously at Genzyme, he was responsible for ongoing management of four global registries for rare diseases. In that capacity, he participated in groundbreaking advancements in the medical treatment of patients and led the registry programs through growth and evolution to meet a wider range of clinical, regulatory, and commercial expectations. Mr. Mantick holds a B.S. degree in Pharmacy from the University of Kentucky and an M.S. degree in Health Policy and Management from the Harvard University School of Public Health.
  • David Brown, Ph.D., Vice President, Epidemiology:  Most recently, Dr. Brown served as Senior Director of Epidemiology at King Pharmaceuticals, which was acquired by Pfizer Inc. Prior to joining King Pharmaceuticals, he held senior positions in epidemiology and global safety surveillance, including serving as epidemiology team leader for oncology and neurosciences at Wyeth Research. Dr. Brown holds a doctorate in epidemiology from the University of Alabama at Birmingham, and earned his Master's degree in public health from Loma Linda University, as well as a Master's degree in cellular and molecular biology from the University of California at Riverside. 
  • Deborah Lubeck, Ph.D.,Vice President, Health Economics and Outcomes Research:  Prior to PAREXEL, Dr. Lubeck served as Vice President of Late Phase Services at a major CRO.  Previously, she was a member of the research faculty at Stanford University and the University of California, San Francisco. Dr. Lubeck has been involved in outcomes research for 25 years and has coauthored over 160 peer-reviewed publications. Her research has focused on the design and analysis of observation
    '/>"/>

  • SOURCE PAREXEL International Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. PAREXEL Advances Early Phase CNS Research Capabilities With Leading Medical Imaging Technology
    2. UCB and PAREXEL Sign Strategic Partnership Agreement
    3. PAREXEL International to Present at Lazard Capital Markets Healthcare Conference and Citi Small/Mid Cap Conference
    4. PAREXEL Commercialization Experts to Present Best-Practice Approaches for Demonstrating Product Value at ISPOR Annual European Congress
    5. PAREXEL Reports First Quarter Fiscal Year 2012 Financial Results
    6. PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value
    7. New PAREXEL Podcast Series to Deliver Clinical Development and Commercialization Thought Leadership
    8. PAREXEL and National University of Singapore Establish Program in Singapore to Meet Increasing Demand in Asia for Clinical Research Talent
    9. PAREXEL Announces Date of First Quarter Fiscal Year 2012 Earnings Release and Conference Call
    10. Experts to Provide Successful Strategies for Global Biopharmaceutical Development and Commercialization at PAREXEL Tokyo Seminar
    11. PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)... According to the ... Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments (HPLC, ... (Immunology, Oncology) & by End User - ... provides a detailed overview of the major ... and strategies impacting the global glycomics enzymes, ...
    (Date:9/30/2014)... A study using a relatively new imaging ... at the composition of carotid artery disease and has ... the disease, a leading cause of stroke. ... September 2010 and May 2012, was featured in the ... American College of Cardiology (JACC) Cardiovascular Interventions. Interventional ...
    (Date:9/30/2014)... BRUNSWICK, N.J., Sept. 30, 2014 The ... Kessler Foundation and New Jersey Health Foundation (NJHF) ... and patient care programs has been announced by ... officer of Kessler Foundation and James M. ... "The experience of New Jersey Health ...
    Breaking Medicine Technology:Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2
    ... Solutions, Inc., the industry leader in innovative shape ... Intramedullary Ankle Fusion Nail. Ankle fusion is performed ... ankle joints, to correct joint deformities or to ... patented design utilizes shape memory alloy technology to ...
    ... Aug. 9, 2011 Eli Lilly and Company (NYSE: ... EVISTA® (raloxifene HCl tablets) therapy for more than three ... & Opinion . The review includes summaries of previously ... on EVISTA use. EVISTA is indicated for the treatment ...
    Cached Medicine Technology:MedShape Solutions Announces FDA 510(k) Clearance of Innovative Ankle Fusion Device 2MedShape Solutions Announces FDA 510(k) Clearance of Innovative Ankle Fusion Device 3Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 2Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 3Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 4Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 5Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 6
    (Date:9/30/2014)... September 30, 2014 Dynamic health ... hampered growth in the Bread Production industry over ... consumers to moderate their consumption of a variety ... premium varieties shrunk the market for white loaf ... proactively responded by introducing more nutritious products to ...
    (Date:9/30/2014)... A University of Maryland-led research team has been ... National Institutes of Health (NIH) to develop new ... further our understanding of how large networks of ... information. This knowledge will help researchers identify the ... drive behavior, like decision-making and speaking, and alterations ...
    (Date:9/30/2014)... September 30, 2014 The American ... to help diabetics curb their sweet tooth, but the ... this September, suggests that zero-calorie sweeteners may actually ... diabetes. , The Weizmann Institute of Science in ... artificial sweeteners to mice, the mice developed glucose intolerance. ...
    (Date:9/30/2014)... Regenerative Medicine Solutions (RMS) is set ... Nashville, Tennessee. RMS welcomes the launch of an entirely ... of a new treatment center for the Lung Institute. ... Institute to Nashville, the hope is to bring awareness ... diagnosed and undiagnosed. With Nashville being a hub for ...
    (Date:9/30/2014)... -- Medicare should cover low-dose computed tomography lung cancer ... a coalition of more than 60 patient and medical ... Cancer Alliance, the Society of Thoracic Surgeons, the American ... American Society of Clinical Oncology, made its point in ... Medicare & Medicaid Services (CMS). Such screening reduces ...
    Breaking Medicine News(10 mins):Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Regenerative Medicine Solutions Expanding 2Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2
    ... and the Fastest Growing Healthcare Staffing Company with over 100 million Dollars ... ... Jackson Healthcare (JH) has been named the 5th largest healthcare staffing ... Compiled each year by SIA, firms are ranked on the list ...
    ... for their prolonged seizures with the sedative propofol may ... New research presented at CHEST 2008, the 74th annual ... Physicians (ACCP), shows that the use of propofol as ... (RSE), prolonged seizures that do not respond to initial ...
    ... look at the effect of neighborhood greenness on ... the Indiana University School of Medicine, Indiana University-Purdue ... that higher neighborhood greenness is associated with slower ... year period, regardless of residential density. , "Previous ...
    ... psychiatric cases in Michigan,s rural areas, particularly among children and ... colleges of Osteopathic Medicine and Human Medicine meet each week ... , On a typical morning, doctors in MSU,s Department of ... far away as Cadillac or Marquette all without leaving ...
    ... channel blockers could inhibit Plavix action, study says , , ... drugs, which are widely prescribed for coronary conditions, might ... new study says. , Calcium channel blockers appear to ... said the report by Austrian physicians published online Oct. ...
    ... Brachytherapy Treatment, ST. LOUIS, Oct. 27 ... to deliver radioactive seed therapy,in the prostate. The ... stabilizes the prostate during procedures. With the gland ... images to map,and confirm placement of radiation., ...
    Cached Medicine News:Health News:Jackson Healthcare Named 5th Largest Healthcare Staffing Company 2Health News:Jackson Healthcare Named 5th Largest Healthcare Staffing Company 3Health News:Anti-seizure drug could be fatal 2Health News:Neighborhood greenness has long term positive impact on kids' health 2Health News:Neighborhood greenness has long term positive impact on kids' health 3Health News:MSU doctors bring much-needed psychiatric care to rural areas via technology 2Health News:Common Heart Drugs May Hamper Blood Thinner 2Health News:Common Heart Drugs May Hamper Blood Thinner 3Health News:Doctors Test Advanced Tool for Treating Prostate Cancer 2
    ... Lomb PMMA Anterior Chamber Intraocular Lenses are ... in patients 60 years of age or ... removed by primary intracapsular cataract extraction; or ... a structural reason that the anterior chamber ...
    ... Amvisc Plus is the preferred viscoelastic ... viscoelastic that reliably works from the start ... unique, moderately cohesive profile of this viscoelastic ... vacuum forces associated with phacoemulsification remove only ...
    ... ENDOGEL is a sterile, non-pyrogenic solution ... is supplied in a disposable single ... fitting, delivering 0,85 ml. Sodium ... of repetitive chains of disaccharides, glucoronate, ...
    ... a sterile, non-pyrogenic, transparent viscoelastic preparation ... molecular weight (average molecular weight 4 ... 23 mg/mL of sodium hyaluronate 5000, ... N-acetylglucosamine and sodium glucuronate linked by ...
    Medicine Products: